Vycor Medical Reports Improved Operating Profit in First Quarter 2026 Driven by International Growth

Vycor Medical, Inc. (OTCQB: VYCO) reported financial results for the first quarter ended March 31, 2026, showing a turnaround to operating profitability driven by international growth. The company, which operates through Vycor Medical and NovaVision divisions, posted revenue of $458,540, a 5% increase from $436,378 in the same period last year.

The Vycor Medical division, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, generated $440,441 in revenue, up 5% from $418,520. Most of the growth came from international markets, a key strategic focus. Gross profit for the division rose 5% to $359,040, maintaining a robust margin of 82%. NovaVision, still in development, contributed $18,099 in revenue, slightly above the prior year's $17,858.

On a GAAP basis, the company reported operating profit of $45,808, compared to an operating loss of $(12,806) in Q1 2025. Net loss available to common stockholders narrowed to $(142,077) from $(200,748), primarily due to preferred stock dividends of $162,185 in each period. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $59,788, up from $20,388. Non-GAAP cash operating expenses decreased to $315,365 from $338,146.

Vycor's positive momentum is supported by growing clinical evidence for VBAS. During 2026, two new peer-reviewed studies were published, bringing the total to 52. One case study highlighted the effectiveness of integrating neuro-navigation systems with VBAS for complex pediatric tumor resection. A retrospective study of 23 patients showed significantly fewer new neurological deficits with VBAS compared to traditional blade retractors, implying safer tumor resection.

Vycor Medical's VBAS is FDA-cleared and used in over 350 U.S. hospitals and internationally, protected by 49 issued and 8 pending patents. NovaVision offers FDA-cleared Visual Restoration Therapy (VRT) and NeuroEyeCoach for vision rehabilitation after stroke or brain injury. The company continues to invest in development to realize the market potential of these therapies.

Management uses non-GAAP measures to evaluate ongoing performance, excluding non-cash items like depreciation and stock-based compensation. For Q1 2026, non-GAAP operating profit was $59,788, and non-GAAP net loss was $(128,097). The company provided a reconciliation of GAAP to non-GAAP results in its release.

For more information, visit www.vycormedical.com, www.vycorvbas.com, or www.novavision.com.